NO20014852D0 - Melanomterapi - Google Patents

Melanomterapi

Info

Publication number
NO20014852D0
NO20014852D0 NO20014852A NO20014852A NO20014852D0 NO 20014852 D0 NO20014852 D0 NO 20014852D0 NO 20014852 A NO20014852 A NO 20014852A NO 20014852 A NO20014852 A NO 20014852A NO 20014852 D0 NO20014852 D0 NO 20014852D0
Authority
NO
Norway
Prior art keywords
melanoma therapy
melanoma
therapy
Prior art date
Application number
NO20014852A
Other languages
English (en)
Other versions
NO20014852L (no
NO328111B1 (no
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20014852D0 publication Critical patent/NO20014852D0/no
Publication of NO20014852L publication Critical patent/NO20014852L/no
Publication of NO328111B1 publication Critical patent/NO328111B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20014852A 1999-04-08 2001-10-05 Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet. NO328111B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08
PCT/US2000/009129 WO2000061175A2 (en) 1999-04-08 2000-04-06 Use of pegylated interferon alpha in melanoma therapy

Publications (3)

Publication Number Publication Date
NO20014852D0 true NO20014852D0 (no) 2001-10-05
NO20014852L NO20014852L (no) 2001-12-06
NO328111B1 NO328111B1 (no) 2009-12-07

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014852A NO328111B1 (no) 1999-04-08 2001-10-05 Anvendelse av et pegylert interferon alfa-2b for fremstilling av et medikament for behandling av en pasient som har melanom som er blitt kirurgisk fjernet.

Country Status (22)

Country Link
EP (3) EP2025344B1 (no)
JP (1) JP2000319195A (no)
CN (1) CN1390132A (no)
AR (1) AR023398A1 (no)
AT (3) ATE419001T1 (no)
AU (1) AU771569B2 (no)
BR (1) BR0009646A (no)
CA (1) CA2303992A1 (no)
CO (1) CO5170404A1 (no)
CY (1) CY1108922T1 (no)
DE (3) DE60020444T2 (no)
DK (2) DK1535622T3 (no)
ES (2) ES2319776T3 (no)
HK (2) HK1032349A1 (no)
HU (1) HU230057B1 (no)
MY (1) MY126763A (no)
NO (1) NO328111B1 (no)
PE (1) PE20010027A1 (no)
PT (2) PT1043026E (no)
TW (1) TWI292320B (no)
WO (1) WO2000061175A2 (no)
ZA (1) ZA200108173B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
EP2025344A1 (en) 2009-02-18
MY126763A (en) 2006-10-31
ATE419001T1 (de) 2009-01-15
PE20010027A1 (es) 2001-02-05
WO2000061175A2 (en) 2000-10-19
HUP0200775A2 (en) 2002-08-28
ES2239954T3 (es) 2005-10-16
TWI292320B (en) 2008-01-11
HK1032349A1 (en) 2001-07-20
DE60020444T2 (de) 2006-05-04
HUP0200775A3 (en) 2002-09-30
EP1043026B1 (en) 2005-06-01
ATE496631T1 (de) 2011-02-15
CA2303992A1 (en) 2000-10-08
HU230057B1 (hu) 2015-06-29
DE60045591D1 (de) 2011-03-10
ZA200108173B (en) 2003-01-06
BR0009646A (pt) 2002-02-05
PT1535622E (pt) 2009-03-19
AU4204600A (en) 2000-11-14
EP1535622B1 (en) 2008-12-31
CO5170404A1 (es) 2002-06-27
WO2000061175A3 (en) 2001-02-01
EP2025344B1 (en) 2011-01-26
EP1535622A1 (en) 2005-06-01
EP1043026A3 (en) 2000-12-20
DE60041290D1 (de) 2009-02-12
EP1043026A2 (en) 2000-10-11
AR023398A1 (es) 2002-09-04
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
AU771569B2 (en) 2004-03-25
DK1535622T3 (da) 2009-04-20
JP2000319195A (ja) 2000-11-21
ATE296639T1 (de) 2005-06-15
CN1390132A (zh) 2003-01-08
DE60020444D1 (de) 2005-07-07
ES2319776T3 (es) 2009-05-12
HK1075416A1 (en) 2005-12-16
PT1043026E (pt) 2005-09-30
DK1043026T3 (da) 2005-07-04
CY1108922T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
DK1637127T3 (da) Terapeutisk mikroskum
DE69924365D1 (de) Massagegerät
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE60017816D1 (de) Herzschrittmacher
DE60016600D1 (de) Herzschrittmacher
DE59911113D1 (de) Herzschrittmacher
DE50015795D1 (de) Sektionaltor
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE69916133D1 (de) Elektro-neuro-adaptiver stimulator
DE60013608D1 (de) Herzschrittmacher
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE60016452D1 (de) Herzschrittmacher
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
DE60045591D1 (de) Melanomtherapie
ATE440824T1 (de) Nitro-sulfobenzamide
DE10085167T1 (de) Gangumschalteinrichtung
ATA203199A (de) Ablauf
AT500658A3 (de) Isolierplatte
DE1190182T1 (de) Gasfeder

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MM1K Lapsed by not paying the annual fees